Others Hesitate,
We Innovate.

MAY 5-8


Panel Participation

Session Date & Time: Wednesday May 8th | 8:00 AM - 9:00 AM

Discussion Leader: Wei-Shi (Danny) Yeh, PhD, Executive Director, AESARA; Burlingame, CA, USA
Ebony Dashiell-Aje, PhD, Executive Director & Head, Patient Centered Outcomes Science, BioMarin Pharmaceutical, Inc.; San Rafael, CA, USA
Natalie Engmann, PhD, Associate Director, Clinical Outcomes Lead, Denali Therapeutics; South San Francisco, CA, USA
Selena Daniels, PharmD, PhD, Deputy Division Director, Division of Clinical Outcome Assessment, Food and Drug Administration; Silver Spring, MD, USA

Session Date & Time: ​Monday, May 6, 2024 | 11:30 AM-12:00 PM​

Christopher Tutino, BS, MBA, HEOR, Gilead Sciences; San Francisco, CA, USA
Yamini Misra, BS, MBA, Executive Director, AESARA;  Houston, TX, USA


News Alert!

AESARA is excited to announce that ATLAS, your customizable solution for integrated evidence generation planning (IEGP) in pharma, is now AI-enabled! Meet with us to learn how to realize the benefits of leveraging AI in your IEGP. 

Ready to experience the future of integrated evidence generation planning? Join us at ISPOR or schedule a meeting to sign up for our three-month trial and continue exploring the potential of AI with us!

Summarize Evidence with Ease

Struggling to manage volumes of data in your evidence repository? ATLAS AI streamlines the process, prepopulating metadata fields and concisely summarizing publications trough a value and access lens.

Enhanced Alignment and Connectivity

ATLAS doesn’t just organize data it continues to enhance alignment across functions and geographies as well as connect evidence generation tactics with the value messages they support. Create a unified strategy with ATLAS, focused on long-term success. 

AI-assisted Value Proposition Framing

Let ATLAS AI take the first stab at framing your value propositionUsing your product value messages, ATLAS AI can generate a concise and targeted summary that communicates your product’s unique value and unmet needs it is addressing. 


HEOR Benchmarking Report: 2024

Insights on how Biopharma companies rank among their peers, strengths and weaknesses of HEOR organizations, and areas for improvement in value and evidence generation to enable patient access

Health Economics for Value and Access: An Interactive E-Learning Experience

This e-learning module is designed to provide a comprehensive yet accessible introduction to health economics concepts, focusing on the evaluation of value of new treatments versus their comparators and how access is determined. 

Inflation Reduction Act Decision Guide and Revenue Model for Early Phase Products

AESARA can leverage ongoing experiences with IRA negotiations to help develop a comprehensive “roadmap” for key assets in early phase development through a 3-phase process

Couldn't join us at ISPOR Atlanta?No worries 😉

Scan and Experience theENDLESS POSSIBILITIES

Play Video

Catch up with LinkedIn

AESARA is hosting an exclusive event by invitation on the evening of Monday, May 6th, commencing at 6 PM

Contact us

Fill out the form below, and we will be in touch shortly.